Bod Science Limited Announces Pharmacokinetic Study to Confirm the Bioavailability of Aqua Phase Submitted for Ethics Approval
immediately once ethics approval is received. The PK study will recruit 12 subjects and will continue for 4 weeks. Results are expected in June 2023. This is the key test for the pharmaceutical application of the process technology, with a successful outcome expected to provide the base line data to support commercialisation discussions, expand Bod's value proposition, lead to new and novel delivery formats, higher margin and revenue accretion.